S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

ADC Therapeutics (ADCT) Stock Forecast, Price & News

+0.04 (+0.57%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
276,430 shs
Average Volume
301,518 shs
Market Capitalization
$482.93 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ADCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADC Therapeutics logo

About ADC Therapeutics

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$33.92 million
Book Value
$2.41 per share


Net Income
$-230.03 million
Net Margins
Pretax Margin




Free Float
Market Cap
$482.93 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.85 out of 5 stars

Medical Sector

747th out of 1,416 stocks

Pharmaceutical Preparations Industry

360th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

ADC Therapeutics (NYSE:ADCT) Frequently Asked Questions

Is ADC Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADC Therapeutics stock.
View analyst ratings for ADC Therapeutics
or view top-rated stocks.

When is ADC Therapeutics' next earnings date?

ADC Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for ADC Therapeutics

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) announced its earnings results on Monday, May, 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.54. ADC Therapeutics had a negative trailing twelve-month return on equity of 102.72% and a negative net margin of 242.69%. During the same period in the previous year, the firm posted ($0.67) earnings per share.
View ADC Therapeutics' earnings history

What price target have analysts set for ADCT?

5 analysts have issued 1-year price targets for ADC Therapeutics' stock. Their forecasts range from $30.00 to $54.00. On average, they anticipate ADC Therapeutics' share price to reach $41.60 in the next year. This suggests a possible upside of 490.1% from the stock's current price.
View analysts' price targets for ADC Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are ADC Therapeutics' key executives?
ADC Therapeutics' management team includes the following people:
  • Dr. Christopher J. Martin Ph.D., Co-Founder, CEO & Director (Age 63)
  • Mr. Michael Forer L.L.B., Vice Chairman, Exec. VP & Gen. Counsel (Age 56)
  • Ms. Jennifer Creel, Chief Financial Officer (Age 51)
  • Mr. Robert A. Schmidt, VP, Corp. Controller & Chief Accounting Officer (Age 45)
  • Amanda Hamilton, Investor Relations Officer
  • Ms. Susan Romanus, Chief Compliance Officer (Age 56)
  • Dr. Peter Greaney Ph.D., Head of Corp. Devel. (Age 42)
  • Ms. Kimberly Pope, Sr. VP & Chief HR Officer (Age 55)
  • Dr. Patrick van Berkel, Sr. VP of R&D (Age 53)
  • Dr. Michael Mulkerrin, Head of Chemistry Manufacturing & Control and VP
What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include (HON), CVS Health (CVS), Raytheon Technologies (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an IPO on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

What is ADC Therapeutics' stock symbol?

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (4.96%), Matrix Capital Management Company LP (0.58%), Employees Retirement System of Texas (0.45%), Principal Financial Group Inc. (0.44%), BlackRock Inc. (0.44%) and Walleye Capital LLC (0.36%).

Which institutional investors are selling ADC Therapeutics stock?

ADCT stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., and Simplex Trading LLC.

Which institutional investors are buying ADC Therapeutics stock?

ADCT stock was bought by a variety of institutional investors in the last quarter, including Matrix Capital Management Company LP, JPMorgan Chase & Co., Walleye Capital LLC, Employees Retirement System of Texas, BlackRock Inc., Allianz Asset Management GmbH, Prospera Financial Services Inc, and Advisor Group Holdings Inc..

How do I buy shares of ADC Therapeutics?

Shares of ADCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADC Therapeutics' stock price today?

One share of ADCT stock can currently be purchased for approximately $7.05.

How much money does ADC Therapeutics make?

ADC Therapeutics has a market capitalization of $482.93 million and generates $33.92 million in revenue each year. The company earns $-230.03 million in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does ADC Therapeutics have?

ADC Therapeutics employs 312 workers across the globe.

What is ADC Therapeutics' official website?

The official website for ADC Therapeutics is www.adctherapeutics.com.

How can I contact ADC Therapeutics?

The company can be reached via phone at 41-21-653-0200 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.